Strategy suggests ways to prepare for emerging superbugs
As dangerous bacteria grow more savvy at evading antibiotics, researchers are seeking new ways to counterattack. Rather than design new drugs from scratch, some scientists are searching for ways to block the microbes’ evasive maneuvers. If resistance can be shut down, current drugs should remain effective.
That concept is demonstrated in a new study from Washington University School of Medicine in St. Louis. The researchers discovered compounds that block resistance to a major class of antibiotics called tetracyclines. If developed into a drug, such a compound could be given in combination with a tetracycline, should the infection become resistant to tetracycline alone. These types of compounds do not have a direct antimicrobial effect — if given alone, they would not kill bacteria. Instead, they knock down the bacteria’s ability to survive treatment with specific antibiotics.
The research, performed in bacteria grown in the lab, is published May 8 in the journal Nature Chemical Biology.
“These compounds inhibit the ability of tetracycline-resistant bacteria to destroy tetracycline,” said co-senior author Gautam Dantas, an associate professor of pathology and immunology. “We’re gunking up the resistance machinery of bacteria capable of destroying tetracycline. If these bugs can’t chew up this antibiotic anymore, they are re-sensitized to the effects of the drug.”
Tetracyclines are prescribed for a wide variety of bacterial infections, including pneumonia and other infections of the respiratory tract; acne and other skin infections; infections of the genital and urinary systems; and the bacterial infection that causes stomach ulcers. They also are widely used in large farming operations, including the dairy and fish industries.
Despite tetracyclines’ widespread use, bacterial infections have not yet demonstrated aggressive resistance to these drugs via destruction mechanisms. Some bacteria are resistant to tetracyclines through other means, such as pumping the drug out of the cell or blocking the drug from reaching its target, but these strategies are not as effective as destroying the drug entirely. Dantas said conditions are favorable for this destructive type of resistance to ramp up.
The researchers discovered these resistance inhibitor compounds by first conducting genetic surveys of bacteria living in soils from different parts of the country; they were interested in understanding the extent of antibiotic resistance present in bacteria living in the environment. Using a genomic technique that Dantas’ laboratory helped develop, the researchers previously had isolated small fragments of bacterial DNA from soils and screened those pieces for genes that can confer antibiotic resistance in infectious bacteria. These studies demonstrated that soil bacteria are packed with genes that — if transferred into disease-causing bacteria — would allow that bacteria to survive treatment with many common antibiotics.
According to Dantas, one set of genes stood out because the researchers could not find these sequences listed in any genomic database, and these novel genes allowed bacteria to break down tetracycline antibiotics, a problem that has not yet occurred in the many patients treated with tetracyclines.
While the genes are not yet widely present in bacteria causing infections, Dantas and his team determined the genes were at high risk of spreading because of tetracyclines’ widespread use and the fact that even appropriate antibiotic use favors survival of resistant bacteria. In addition, some of the newly discovered resistance genes were located near sections of the bacterial genome known to be capable of jumping between even distantly related bacteria. The resistance genes enable the bacteria to manufacture proteins the researchers dubbed tetracycline destructases because of their ability to break apart tetracycline.
Dantas formed partnerships with co-senior authors Timothy A. Wencewicz, an assistant professor of chemistry, and Niraj H. Tolia, PhD, an associate professor of molecular microbiology, to determine how these destructases work and develop inhibitors that interfere with their ability to break apart tetracycline. Dantas pointed out the importance of collaborations across disciplines to tackle the complex problem of antibiotic resistance. In this case, the researchers are combining expertise in genetics, chemistry, structural microbiology and big data analysis to design inhibitors of tetracycline destructases.
Bacteria carrying tetracycline destructases are not yet at the level of danger posed by superbugs such as carbapenem-resistant Enterobacteriaceae (CREs), but their resistance strategies work in similar ways in terms of the ability to destroy an antibiotic. Last year, a CRE infection resistant to all available antibiotics led to the death of a Nevada woman with a recent history of hospitalizations outside the United States.
Targeting resistance has had success in some bacterial infections that have become resistant to another important class of drugs called beta-lactams, which includes penicillin. Tetracycline destructase inhibitors would serve a similar function to beta-lactamase inhibitors. These inhibitors often have been developed alongside their associated beta-lactam drugs and have helped some beta-lactams regain their effectiveness.
Emphasizing the timeliness of the research, Dantas said there is evidence these tetracycline destructase resistance genes are beginning to ramp up the threat to patients with bacterial infections.
“Since we started this work three years ago, one tetracycline destructase now has been found to be present in four of the six most deadly pathogens, as defined by the Centers for Disease Control and Prevention,” Dantas said. “This is our motivation for working to find inhibitors of tetracycline destructases.”
This work was supported by the National Institutes of Health (NIH), grant numbers R01 AI123394 and T32 GM007067.
Park J, Gasparrini AJ, Reck MR, Symister CT, Elliot JL, Vogel JP, Wencewicz TA, Dantas G, Tolia NJ. Plasticity, dynamics and inhibition of emerging tetracycline-resistance enzymes. Nature Chemical Biology. May 8, 2017.
Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked seventh in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.